These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 36894911)

  • 1. Identification of inadequate responders to advanced therapy among commercially-insured adult patients with Crohn's disease and ulcerative colitis in the United States.
    Gibble TH; Naegeli AN; Grabner M; Isenberg K; Shan M; Teng CC; Curtis JR
    BMC Gastroenterol; 2023 Mar; 23(1):63. PubMed ID: 36894911
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identifying inadequate response among patients with ankylosing spondylitis and psoriatic arthritis prescribed advanced therapy in a real-world, commercially insured adult population in the USA.
    Hunter T; Grabner M; Birt J; Isenberg K; Shan M; Teng CC; Wu J; Griffing K; Lisse J; Curtis JR
    Clin Rheumatol; 2022 Sep; 41(9):2863-2874. PubMed ID: 35672618
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Medication use among patients with Crohn's disease or ulcerative colitis before and after the initiation of advanced therapy.
    Hunter T; Naegeli AN; Nguyen C; Shan M; Smith JL; Tan H; Gottlieb K; Isenberg K
    BMC Gastroenterol; 2022 Nov; 22(1):474. PubMed ID: 36402945
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Racial or ethnic differences on treatment adherence and persistence among patients with inflammatory bowel diseases initiated with biologic therapies.
    Cai Q; Ding Z; Fu AZ; Patel AA
    BMC Gastroenterol; 2022 Dec; 22(1):545. PubMed ID: 36581802
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-world assessment of therapy changes, suboptimal treatment and associated costs in patients with ulcerative colitis or Crohn's disease.
    Rubin DT; Mody R; Davis KL; Wang CC
    Aliment Pharmacol Ther; 2014 May; 39(10):1143-55. PubMed ID: 24697826
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regional variations in the use of biologics and immunomodulators among Korean patients with inflammatory bowel diseases.
    Han M; Jung YS; Cheon JH; Park S
    J Gastroenterol Hepatol; 2019 Jul; 34(7):1166-1174. PubMed ID: 30672608
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biologic Use Patterns and Predictors for Non-persistence and Switching of Biologics in Patients with Inflammatory Bowel Disease: A Nationwide Population-Based Study.
    Jung YS; Han M; Park S; Cheon JH
    Dig Dis Sci; 2020 May; 65(5):1436-1444. PubMed ID: 31677070
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of a second TNFi vs other biologic or targeted synthetic DMARD following an initial TNFi.
    Asante K; Racsa P; Bloomfield A; Cornett D; Schwab P
    J Manag Care Spec Pharm; 2023 Oct; 29(10):1109-1118. PubMed ID: 37776118
    [No Abstract]   [Full Text] [Related]  

  • 9. Treatment Pathways Leading to Biologic Therapies for Ulcerative Colitis and Crohn's Disease in the United States.
    Siegel CA; Yang F; Eslava S; Cai Z
    Clin Transl Gastroenterol; 2020 Feb; 11(2):e00128. PubMed ID: 32463619
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of corticosteroid-related quality of care measures for ulcerative colitis and Crohn's disease in the United States: a claims data analysis.
    Rubin DT; Patel H; Shi S; Mody R
    Curr Med Res Opin; 2017 Mar; 33(3):529-536. PubMed ID: 27903084
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment Patterns and Sequencing in Patients With Inflammatory Bowel Disease.
    Brady JE; Stott-Miller M; Mu G; Perera S
    Clin Ther; 2018 Sep; 40(9):1509-1521.e5. PubMed ID: 30126706
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment patterns for biologics in ulcerative colitis and Crohn's disease: a Danish Nationwide Register Study from 2003 to 2015.
    Alulis S; Vadstrup K; Borsi A; Nielsen A; Rikke Jørgensen T; Qvist N; Munkholm P
    Scand J Gastroenterol; 2020 Mar; 55(3):265-271. PubMed ID: 32116064
    [No Abstract]   [Full Text] [Related]  

  • 13. Effects of concomitant immunomodulators on the pharmacokinetics, efficacy and safety of adalimumab in patients with Crohn's disease or ulcerative colitis who had failed conventional therapy.
    Colombel JF; Jharap B; Sandborn WJ; Feagan B; Peyrin-Biroulet L; Eichner SF; Robinson AM; Mostafa NM; Zhou Q; Thakkar RB
    Aliment Pharmacol Ther; 2017 Jan; 45(1):50-62. PubMed ID: 27883215
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The incidence of remission and indicators of inadequate response to advanced therapy in patients with ulcerative colitis: results from medical charts in the United Kingdom.
    Lindsay JO; Picker N; Kromer D; Smyth M; Patel H
    Curr Med Res Opin; 2023 May; 39(5):681-689. PubMed ID: 36951899
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early azathioprine/biological therapy is associated with decreased risk for first surgery and delays time to surgery but not reoperation in both smokers and nonsmokers with Crohn's disease, while smoking decreases the risk of colectomy in ulcerative colitis.
    Szamosi T; Banai J; Lakatos L; Czegledi Z; David G; Zsigmond F; Pandur T; Erdelyi Z; Gemela O; Papp M; Papp J; Lakatos PL
    Eur J Gastroenterol Hepatol; 2010 Jul; 22(7):872-9. PubMed ID: 19648821
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of Safety, Medical Resource Utilization, and Treatment Costs by Drug Class for Management of Inflammatory Bowel Disease in the United States Based on Insurance Claims Data.
    Long GH; Tatro AR; Oh YS; Reddy SR; Ananthakrishnan AN
    Adv Ther; 2019 Nov; 36(11):3079-3095. PubMed ID: 31562607
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Corticosteroid Sparing in Inflammatory Bowel Disease is More Often Achieved in the Immunomodulator and Biological Era-Results from the Dutch Population-Based IBDSL Cohort.
    Jeuring SFG; Biemans VBC; van den Heuvel TRA; Zeegers MP; Hameeteman WH; Romberg-Camps MJL; Oostenbrug LE; Masclee AAM; Jonkers DMAE; Pierik MJ
    Am J Gastroenterol; 2018 Mar; 113(3):384-395. PubMed ID: 29317770
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sleep disturbance and risk of active disease in patients with Crohn's disease and ulcerative colitis.
    Ananthakrishnan AN; Long MD; Martin CF; Sandler RS; Kappelman MD
    Clin Gastroenterol Hepatol; 2013 Aug; 11(8):965-71. PubMed ID: 23376797
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacodynamic mechanisms behind a refractory state in inflammatory bowel disease.
    Goll R; Moe ØK; Johnsen KM; Meyer R; Friestad J; Gundersen MD; Kileng H; Johnsen K; Florholmen JR
    BMC Gastroenterol; 2022 Nov; 22(1):464. PubMed ID: 36384462
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Infliximab biosimilar CT-P13 therapy is effective and safe in maintaining remission in Crohn's disease and ulcerative colitis - experiences from a single center.
    Farkas K; Rutka M; Ferenci T; Nagy F; Bálint A; Bor R; Milassin Á; Fábián A; Szántó K; Végh Z; Kürti Z; Lakatos PL; Szepes Z; Molnár T
    Expert Opin Biol Ther; 2017 Nov; 17(11):1325-1332. PubMed ID: 28819991
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.